New oligodendrocytes are generated after neonatal hypoxic-ischemic brain injury in rodents.
Neonatal hypoxic-ischemic (HI) white matter injury is a major contributor to chronic neurological dysfunction. Immature oligodendrocytes (OLGs) are highly vulnerable to HI injury. As little is known about in vivo OLG repair mechanisms in neonates, we studied whether new OLGs are generated after HI injury in P7 rats. Rats received daily BrdU injections at P12-14 or P21-22 and sacrificed at P14 to study the level of cell proliferation or at P35 to permit dividing OLG precursors to differentiate. In P14 HI-injured animals, the number of BrdU+ cells in the injured hemisphere is consistently greater than controls. At P35, sections were double-labeled for BrdU and markers for OLGs, astrocytes, and microglia. Double-labeled BrdU+/myelin basic protein+ and BrdU+/carbonic anhydrase+ OLGs are abundant in the injured striatum, corpus callosum, and the infarct core. Quantitative studies show four times as many OLGs are generated from P21-35 in HI corpora callosa than controls. Surprisingly, the infarct core contains many newly generated OLGs in addition to hypertrophied astrocytes and activated microglia. These glia and non-CNS cells may stimulate OLG progenitor proliferation or induce their migration. At P35, astrogliosis and microgliosis are dramatic ipsilaterally but only a few microglia and some astrocytes are BrdU+. This finding indicates microglial and astrocytic hyperplasia occurs shortly after HI but before the P21 BrdU injections. Although the neonatal brain undergoes massive cell death and atrophy the first week after injury, it retains the potential to generate new OLGs up to 4 weeks after injury within and surrounding the infarct.
Zaidi
Aliya U
AU
Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Bessert
Denise A
DA
Ong
Jennifer E
JE
Xu
Haiyan
H
Barks
John D E
JD
Silverstein
Faye S
FS
Skoff
Robert P
RP
D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000166:cytology / Q000378:metabolism; D001284:Atrophy / Q000473:pathology / Q000503:physiopathology; D015415:Biomarkers; D001973:Bromodeoxyuridine; D002255:Carbonic Acid / Q000378:metabolism; D002452:Cell Count; D016923:Cell Death / Q000502:physiology; D002454:Cell Differentiation; D002455:Cell Division / Q000502:physiology; D002544:Cerebral Infarction / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D005911:Gliosis / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D004676:Myelin Basic Protein / Q000378:metabolism; D009413:Nerve Fibers, Myelinated / Q000473:pathology*; D009836:Oligodendroglia / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013234:Stem Cells / Q000378:metabolism / Q000473:pathology
D015415:Biomarkers; D004676:Myelin Basic Protein; D002255:Carbonic Acid; D001973:Bromodeoxyuridine